Iovance Biotherapeutics Inc
NASDAQ:IOVA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.22
17.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Iovance Biotherapeutics Inc
Wall Street
Price Targets
IOVA Price Targets Summary
Iovance Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for
IOVA
is 24.24 USD
with a low forecast of 10.1 USD and a high forecast of 35.7 USD.
IOVA Last Price Targets
Iovance Biotherapeutics Inc
The latest public price target was made on Oct 24, 2024 by
David Dai
from
UBS
,
who expects
IOVA
stock to
rise by 130%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
David Dai
UBS
|
17
USD
Upside 130% |
1 month ago
Oct 24, 2024
|
UBS Starts Iovanace Biotherapeutics (IOVA) at Buy
StreetInsider
|
Colleen Kusy
Robert W. Baird
|
24
USD
Upside 225% |
4 months ago
Aug 9, 2024
|
Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird
StreetInsider
|
Benjamin Burnett
Stifel Nicolaus
|
23
USD
Upside 212% |
4 months ago
Aug 9, 2024
|
Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel
StreetInsider
|
Joseph Catanzaro
Piper Sandler
|
10
USD
Upside 36% |
4 months ago
Jul 29, 2024
|
Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral
StreetInsider
|
Reni Benjamin
JMP Securities
|
23
USD
Upside 212% |
6 months ago
Jun 20, 2024
|
Iovance Biotherapeutics price target lowered to $23 from $25 at JMP Securities
TheFly
|
|
Benjamin Burnett
Stifel Nicolaus
|
28
USD
Upside 279% |
6 months ago
May 31, 2024
|
Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
StreetInsider
|
|
Joseph Catanzaro
Piper Sandler
|
19
USD
Upside 157% |
9 months ago
Mar 14, 2024
|
Iovanace Biotherapeutics (IOVA) PT Raised to $19 at Piper Sandler
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is IOVA's stock price target?
Price Target
24.24
USD
According to Wall Street analysts, the average 1-year price target for
IOVA
is 24.24 USD
with a low forecast of 10.1 USD and a high forecast of 35.7 USD.
What is Iovance Biotherapeutics Inc's Revenue forecast?
Projected CAGR
442%
The
compound annual growth rate
of Iovance Biotherapeutics Inc's revenue for the next 4 years is
442%.
You don't have any saved screeners yet
